Abstract
Amyloidosis comprises a unique group of diseases that share in common the extracellular deposition of insoluble fibrillar proteins in organs and tissue including the heart. Cardiac amyloidosis could be primary a part of systemic acquired amyloidosis, or a result of heredofamilial amyloidosis. Although the infiltration of the heart from different types of amyloid results in restrictive cardiomyopathy that manifests with refractory congestive heart failure and conduction abnormalities, unequivocal identification of the deposited amyloidogenic protein is mandatory in order to avoid misdiagnosis and inappropriate treatment. Recent developments in imaging techniques and extracardiac tissue biopsy have minimized the need for invasive endomyocardial biopsy for amyloidosis. Despite advances in treatment, the prognosis of a patient with amyloidosis is still poor and depends upon the underlying disease, and the type and degree of dysfunction of the involved organs. Thus, early diagnosis is mandatory because patients with advanced disease are usually too ill for intensive therapy. This review outlines current approaches to diagnosis, assessment of disease severity, and treatment of cardiac amyloidosis.
Similar content being viewed by others
References
Dubrey SW, Cha K, Anderson J et al (1998) The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 91:141–157
Kyle RA, Gertz MA (1995) Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 32:45–59
Kyle RA, Linos A, Beard CM et al (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79:1817–1822
Hazembergh BPC, Van Rijswisk MH (2000) Aspects cliniques de l’amylose AA. In: Grateau G, Benson MD, Delpech M (eds) Les Amyloses. Médicine-Sciences Flammarion, Paris, pp 377–427
Magy-Bertrand N, Dupond JL, Mauny F, Dupond AS, Duchene F, Gil H, Kantelip B, The CRISAP Members (2008) Incidence of amyloidosis over 3 years: the AMYPRO study. Clin Exp Rheum 26:1074–1078
Obici L, Perfetti V, Palladini G, Moratti R, Merlini G (2005) Clinical aspects of systemic amyloid diseases. Biochem Biophys Acta 1753:11–22
Park MA, Mueller PS, Kyle RA et al (2003) Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Medicine 82:291–298
Nestle FO, Burg G (2001) Bilateral carpal tunnel syndrome as a clue for the diagnosis of systemic amyloidosis. Dermatology 202:353–355
Pettersson T, Konttinen YT, Maury CPJ (2008) Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 9(12):2117–2128
Hawkins PN (2002) Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 11:649–655
Gertz MA, Kyle RA (1991) Secondary systemic amyloidosis: response and survival in 64 patients. Medicine 70:246–256
Benson MD, Kincaid JC (2007) The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 36:411–423
Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P (1983) Frequency and distribution of senile cardiovascular amyloid: a clinicopathologic correlation. Am J Med 75:618–623
Murtagh B, Hammill SC, Gertz MA et al (2005) Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol 95:535–537
Feng D, Edwards WD, Krishnaswamy JKO et al (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116:2420–2426
Mueller PS, Edwards WD, Gertz MA (2000) Symptomatic ischemic heart disease resulting from obstructive intramural coronary amyloidosis. Am J Med 109:181–188
Chamarthi B, Dubrey SW, Cha K et al (1997) Features and prognosis of exertional syncope in light-chain associated AL cardiac amyloidosis. Am J Cardiol 80:1242–1245
Falk RH, Rubinow A, Cohen AS (1984) Cardiac arrhythmias in systemic amyloidosis: correlation with echocardiographic abnormalities. J Am Coll Cardiol 3:107–113
Falk RH, Plehn J, Deering T et al (1987) Sensitivity and specificity of the echocardiographic features of cardiac amyloidosis. Am J Cardiol 59:418–422
Klein AL, Hatle LK, Taliercio CP et al (1990) Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 16:1135–1141
Rahman JE, Helou EF, Gelzer-Bell R et al (2004) Noninvasive diagnosis of biopsy-proven cardiac amyloidosis. J Am Coll Cardiol 43:410–415
Bhandari AK, Nanda NC (1983) Myocardial texture characterization by two-dimensional echocardiography. Am J Cardiol 51:817–825
Simons M, Isner JM (1992) Assessment of relative sensitivities of noninvasive tests for cardiac amyloidosis in documented cardiac amyloidosis. Am J Cardiol 69:425–427
Hongo M, Kono J, Yamada H et al (1991) Doppler echocardiographic assessments of left ventricular diastolic filling in patients with amyloid heart disease. J Cardiol 21:391–401
Koyama J, Ray-Sequin PA, Davidoff R et al (2002) Usefulness of pulsed tissue Doppler imaging for evaluating systolic and diastolic left ventricular function in patients with AL (primary) amyloidosis. Am J Cardiol 89:1067–1071
Porciani MC, Lilli A, Perfetto F et al (2009) Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid 16:63–70
Koyama J, Ray-Sequin PA, Falk RH (2003) Longitudinal myocardial function assessed by tissue velocity, strain, and strain rate tissue Doppler echocardiography in patients with AL (primary) cardiac amyloidosis. Circulation 107:2446–2452
Porciani MC, Cappelli F, Perfetto F et al (2010) Rotational mechanics of the left ventricle in AL amyloidosis. Echocardiography 27:1061–1068
Notomi Y, Martin-Miklovic MG, Oryszak SJ, Shiota T, Deserranno D, Popovic ZB, Garcia MJ, Greenberg NL, Thomas JD (2006) Enhanced ventricular untwisting during exercise: a mechanistic manifestation of elastic recoil described by Doppler tissue imaging. Circulation 113:2524–2533
Rapezzi C, Merlini G, Quarta CC et al (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120:1203–1212
Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E et al (2005) Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 111:186–193
Perugini E, Rapezzi C, Piva T et al (2006) Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 92:343–349
Perugini E, Guidalotti PL, Salvi F et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46:1076–1084
Dispenzieri A, Kyle RA, Gertz MA et al (2003) Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 361:1787–1789
Dispenzieri A, Gertz M, Kyle R et al (2004) Serum cardiac troponins and N-terminal probrain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22(18):3751–3757
Palladini G, Lavatelli F, Russo P et al (2006) Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 107:3854–3858
Kristen AV, Giannitsis E, Lehrke S, Hegenbart U, Konstandin M et al (2010) Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin-T assay. Blood 116:2455–2461
Palladini G, Barassi A, Klersy C, Pacciolla R, Milani P et al (2010) The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 116:3426–3430
Gertz MA, Merlini G (2010) Definition of organ involvement and response to treatment in AL amyloidosis: un updated consensus opinion (abstract). Amyloid 17(s1):48
Duston MA, Skinner M, Meenan RF, Cohen AS (1989) Sensitivity, specificity, and predictive value of abdominal fat aspiration for the diagnosis of amyloidosis. Arthritis Rheum 32:82–85
Lavatelli F, Perlman DH, Spencer B et al (2008) Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics 7:1570–1583
Falk RH, Comenzo RL, Skinner M (1997) The systemic amyloidoses. N Engl J Med 337:898–909
Cueto-Garcia L, Reeder GS, Kyle RA et al (1985) Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol 6:737–743
Klein AL, Hatle LK, Taliercio CP et al (1991) Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. Circulation 83:808–816
Ghio S, Perlini S, Palladini G et al (2007) Importance of the echocardiographic evaluation of right ventricular function in patients with AL amyloidosis. Eur J Heart Fail 9:808–813
Koyama J, Falk RH (2010) Prognostic significance of strain Doppler imaging in light-chain amyloidosis. J Am Coll Cardiol Imag 3:333–342
Bellavia D, Pellikka PA, Al-Zahrani GB et al (2010) Independent predictors of survival in primary systemic (AL) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study. J Am Soc Echocardiogr 23:643–652
Gillmore JD, Lovat LB, Persey MR, Pepys MB, Hawkins PN (2001) Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 358:24–29
Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R (2008) Renal involvement in systemic amyloidosis An Italian collaborative study on survival and renal outcome Nephrol. Dial Transplant 2:941–951
Lachmann HJ, Goodman HJB, Gilbertson JA et al (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356:2361–2371
Rapezzi, C. Perugini E, Salvi F et al. (2006) Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 13:143–153
Rapezzi C, Quarta CC, L Riva et al (2010) Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 7:398–408
Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 165:1425–1429
Dubrey SW, Cha K, Skinner M, LaValley M, Falk RH (1997) Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart 78:74–82
Pollak A, Falk RH (1993) Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 104:618–620
Rubinow A, Skinner M, Cohen AS (1981) Digoxin sensitivity in amyloid cardiomyopathy. Circulation 63:1285–1288
Dubrey S, Pollak A, Skinner M, Falk RH (1995) Atrial thrombi occurring during sinus rhythm in cardiac amyloidosis: evidence for atrial electromechanical dissociation. Br Heart J 74:541–544
Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H et al (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death heart rhythm. Heart Rhythm 5:235–240
Skinner M, Sanchorawala V, Seldin DC et al (2004) High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 140:85–93
Sanchorawala V, Wright DG, Seldin DC et al (2004) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant 33:381–388
Palladini G, Perfetti V, L Obici et al (2004) The association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis ineligible for stem cell transplantation. Blood 103:2936–2938
Palladini G, Perfetti V, Perlini S et al (2005) The combination of thalidomide and intermediate dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 105:2949–2951
Sanchorawala V, Finn KT, Fennessey S et al (2007) Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109:492–496
Moreau P, Jaccard A, Benboubker L et al (2010) Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed AL amyloidosis: a multicenter phase 1/2 dose escalation study. Blood 116:4777–4782
Kumar S, Hayman SR, Buadi F et al. (2009) A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis. Blood (ASH Annual Meeting Abstracts) 114 (abstr 3853)
Dispenzieri A, Gertz MA, Hayman SR et al (2010) Pomalidomide and dexamethasone for previously treated AL: a phase 2 study. Amyloid 17(s1):87
Reece D, Sanchorawala V, Hegenbart U et al (2009) Weekly and twice-weekly bortezomib in patients with systemic AL-amyloidosis: results of a phase 1 dose escalation study. Blood 114:1489–1497
Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2008) Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 93:295–298
Kastritis E, Anagnostopoulos A, Roussou M et al (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92:1351–1358
Kastritis E, Wechalekar AD, Dimopoulos MA et al (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28:1031–1037
Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology 43:1405–1408
Miller SR, Sekijima Y, Kelly JW (2004) Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 84:545–552
Coelho T, Maia L, Martin da Silva A (2010) Tafamidis (Fx-1006A): a first-in-class disease-modifying therapy for transthyretin familial amyloid. Amyloid 17(S1):75–76
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Perfetto, F., Cappelli, F., Bergesio, F. et al. Cardiac amyloidosis: the heart of the matter. Intern Emerg Med 8, 191–203 (2013). https://doi.org/10.1007/s11739-011-0647-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11739-011-0647-y